Myelodysplastic syndrome in a patient with adult T-cell leukaemia.
A 53-year-old female who developed myelodysplastic syndrome (MDS) after chemotherapy for adult T-cell leukaemia (ATL) is described. The latent period of therapy-related MDS (t-MDS) from the time of diagnosis of ATL was approximately 35 months. Cytogenetic analysis of the bone marrow cells at the time of diagnosis of t-MDS revealed a clonal abnormality; 46,XX,add(7)(p13), der(17)t(3;17)(p11;p13). Although monoclonal integration of human T lymphotropic virus type I (HTLV-I) proviral DNA was detected in the peripheral blood lymphocytes at ATL diagnosis, bone marrow cells at t-MDS diagnosis did not show monoclonal integration of HTLV-I. To our knowledge, this is the first report of t-MDS associated with ATL.
Kawabata
H
H
Department of Haematology, Imamura Bun-in Hospital, Kagoshima.
Utsunomiya
A
A
Hanada
S
S
Makino
T
T
Takatsuka
Y
Y
Takeuchi
S
S
Suzuki
S
S
Suzumiya
J
J
Ohshima
K
K
Horiike
S
S
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015139:Blotting, Southern; D004279:DNA, Viral / Q000302:isolation & purification; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007621:Karyotyping; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*
D000970:Antineoplastic Agents; D004279:DNA, Viral